Our Take
Regional proximity beats centralized hubs when iteration speed and regulatory alignment matter more than cost alone.
Why it matters
Biopharma companies are decoupling from single-market strategies to balance cost, quality, and regulatory risk across regions. Korea's government designation of biotech as strategic, combined with quality standards aligned to North American and European norms, is creating a credible alternative to China's cost advantage and Japan's established infrastructure.
Do this week
Bioprocess development teams: audit your current support model against regional lab availability in your target manufacturing regions before committing to the next 18-month program cycle.
Ecolab plants first bioprocessing lab in Asia
Ecolab Life Sciences opened a bioprocessing applications lab in Dongtan, Korea this spring, supporting process development from early- to commercial-scale, with a focus on downstream purification for biologics. The move signals a broader industry shift away from purely centralized expertise toward regional support hubs positioned to serve local clients in compatible time zones.
Jessay Devassy, global R&D director at Ecolab, framed the rationale plainly: "Being in Korea allows the exchange of ideas in an iterative fashion, so knowledge moves seamlessly between regions. That's much easier if you're in their proximity." Proximity reduces cycle time for troubleshooting and reduces the friction of async collaboration across continents.
Korea's appeal rests on three factors. First, it has a established manufacturing history in biologics. Second, it is evolving from a manufacturing hub into a full-stack biopharma ecosystem spanning R&D through clinical development. Third, its quality standards align with North American and European regulatory frameworks, reducing the perception of regulatory risk for global clients sourcing there.
Government backing and regional competition reshape pharma geography
The Korean government designated biopharma as a strategic industry after COVID-19 and restated the commitment in 2023's Third Five-Year Comprehensive Plan. The stated goals are sharp: develop two blockbuster drugs by 2027, double pharmaceutical exports to $16 billion, and position Korea in the top six nations for pharmaceutical development globally.
Capital is flowing. Venture investments in biotech and medical companies reached $830 million in 2025, up 11% year-over-year, and total biotech venture investment rose more than 29% from 2024 (company-reported). Continuous bioprocessing is expected to grow at a compound annual rate of nearly 20% between 2025 and 2030, with revenues exceeding $21 million (per Grand View Horizon).
However, Korea faces stiff competition. India is the fastest-growing Asia-Pacific market. China holds the cost advantage in manufacturing and development and is the largest biopharma market in the region. Japan has more established domestic biomanufacturing infrastructure and leads projected continuous bioprocessing revenue through 2030. Korea currently generates 2.2% of global continuous bioprocessing revenue and is navigating regulatory complexity in a crowded field.
Devassy positioned Korea "somewhere in between" China and Japan: technically strong but still building global competitive credibility. The Ecolab lab is framed as a first step toward making global expertise accessible to growing Asian markets, not a bet that Korea will displace either competitor.
Map your regional support strategy against regulatory and cost trade-offs
If your development program is scaling toward manufacturing, the location of process support matters more than headlines suggest. A local lab in your target manufacturing region cuts iteration time and reduces the risk of regulatory misalignment discovered late in the program. Korea's aligned quality standards and growing ecosystem offer a middle ground between China's cost and Japan's institutional maturity.
The broader lesson: centralized expertise is no longer the default model. If your biopharma company is still routing all process development through a single regional hub, you are trading speed and alignment for coordination simplicity. The industry is decoupling those. Audit whether your current support geography matches your actual manufacturing footprint.